Annals of Indian Academy of Neurology
: 2022  |  Volume : 25  |  Issue : 4  |  Page : 735--738

Severe microcephaly and rapid deterioration due to cortical atrophy in early infancy: Consider TRAPPC4 trappopathy

Akgun Olmez1, Selcan Zeybek2,  
1 Pediatric Neurology Private Clinic, Denizli, Turkey
2 Department of Medical Genetics, Faculty of Medicine, Tınaztepe University, İzmir, Turkey

Correspondence Address:
Akgun Olmez
Pediatric Neurologist, Pediatric Neurology Private Clinic, Saltak Caddesi Yeşil Apt, No: 50/5 Denizli

How to cite this article:
Olmez A, Zeybek S. Severe microcephaly and rapid deterioration due to cortical atrophy in early infancy: Consider TRAPPC4 trappopathy.Ann Indian Acad Neurol 2022;25:735-738

How to cite this URL:
Olmez A, Zeybek S. Severe microcephaly and rapid deterioration due to cortical atrophy in early infancy: Consider TRAPPC4 trappopathy. Ann Indian Acad Neurol [serial online] 2022 [cited 2022 Dec 9 ];25:735-738
Available from:

Full Text

Dear Editor,

Trappopathies are a group of disorders related to the TRAnsport Protein Particle (TRAPP) associated proteins, which have critical roles in cellular trafficking events, autophagy and TRAPP proteins are essential for dendritic spine morphogenesis.[1],[2] TRAPPC4 is one of the core proteins of the TRAPP complex and the number of diseases associated with mutations of the genes encoding the TRAPP complex is increasing.[1] Different mutations affecting the TRAPP complex may share some overlapping features, like microcephaly, seizures, intellectual disability, neurodevelopmental regression and abnormal cranial magnetic resonance imaging (MRI).[1] Reported features of trappopathies include skeletal disorder, spondyloepiphyseal dysplasia tarda and a febrile illness-induced encephalopathy and neurodevelopmental delay in TRAPPC2 and TRAPPC2L, intellectual disability, microcephaly, and thin corpus callosum (TCC) in both TRAPPC6 and TRAPPC9, autosomal recessive mental retardation 13 due to TRAPPC9, elevated creatinine kinase (CK) and lactate, liver disease and muscular disorders (either myopathy or limb-girdle muscular dystrophy and alpha-dystroglycanopathy) in TRAPPC11 related diseases, and microcephaly, severe developmental delay, seizures, and brain abnormalities such as brain atrophy, agenesis of corpus callosum or pons hypoplasia in TRAPPC12.[1]

Van Bergen et al.[2] recently described a pathogenic homozygous c.454+3A>G variant (MIM: 610971) in the TRAPPC4 gene which encodes the trafficking protein particle complex, subunit C4 (TRAPPC4) which resulted in a common phenotype in three unrelated families. Patients all had progressive microcephaly due to severe brain atrophy, spastic quadriparesis, early-onset seizures, profound developmental delay, and common facial dysmorphic features including bitemporal narrowing, thick eyebrows, full cheeks, long filtrum, wide mouth, thin and tinted upper lip, and pointed chin.[2],[3] This phenotype was described by Van Bergen et al.[2] is also known as NEDESBA (MIM: 618741); Neurodevelopmental Disorder with Epilepsy, Spasticity and Brain Atrophy.[3] Herein, we report a patient with the same homozygous c.454+3A>G variant of TRAPPC4, diagnosed by whole-exome sequencing (WES) after rapid deterioration of electroencephalogram (EEG) and MRI findings.

 Case Report

A three and half month-old girl was admitted to the pediatric neurology clinic because of small head size, restlessness and staring attacks. She was born at 37 weeks with a birth weight of 2500 g, after an uneventful pregnancy, as the first child of second-degree consanguineous Turkish parents. On physical examination, her weight was 5745 g (-0.44 standard deviations [SDs]), and head circumference (HC) of 36 cm (-4.2 SDs).[4] She had atopic dermatitis on her cheeks due to multiple food allergy and subtle dysmorphic features, including bi-temporal narrowing, thick eyebrows, long eyelashes, strabismus, long filtrum, thin upper lip, pointed chin, low set ears, and high arched palate; overriding on the right foot was also noted [Figure 1]a. Neurological examination revealed spasticity in all extremities. She had fixation to the face without visual pursuit while no optic atrophy was detected. Informed patient consent had been obtained from the parents both for genetic workup and patient's photograph.{Figure 1}

On laboratory examination, routine blood tests, including total CK, aspartate transaminase (AST), alanine aminotransferase (ALT) and serum lactate levels were all normal. Immunoglobulin (Ig) levels showed low IgA, suggesting partial deficiency of IgA. Thorough metabolic workup including serum amino acid and acylcarnitine analysis, urine organic acid profile, serum lysosomal enzymes for GM1 and GM2 gangliosidosis, Krabbe disease, metachromatic leucodystrophy (MLD), and enzyme levels for neuronal ceroid lipofuchsinosis (NCL) type 2 did not reveal any pathology. Karyotype analysis and microarray analysis were normal. Her newborn hearing-screening test was reported to be normal. Electroencephalography during sleep showed epileptiform activity over the posterior regions of her brain [Figure 2]a and enlarged subarachnoid spaces were reported on cranial MRI [Figure 1]b. She was put on levetiracetam (LEV) treatment, although infrequent clonic seizures occurred despite LEV therapy of 40 mg/kg/day. At the age of five and a half months, a home video showed spasms. Her EEG during sleep showed excessive voltage suppression at 10 and 7 microvolts with slow and sharp waves persisting over the posterior regions [Figure 2]b and [Figure 2]c. Cranial MRI showed brain atrophy [Figure 1]c and [Figure 1]d. Levetiracetam was replaced by topiramate. Whole exome sequencing revealed a homozygous splicing change in the TRAPPC4 gene (hg19:chr11:g. 118890966A>G; TRAPPC4: ENST00000533632.1: c. 454+3A>G). Segregation analysis by Sanger sequencing showed both healthy parents were heterozygous for the same variant.{Figure 2}

At 13 months of age she had a weight of 5800 g (-5.27 SDs) and HC of 36.5 cm (-7.49 SDs). Severe cognitive and motor disability, no eye-tracking or visual pursuit, exotropia, bilateral optic atrophy, and persistent spasticity in spite of baclofen treatment and a physical rehabilitation program were noted. She had had no obvious seizure on topiramate treatment of 5 mg/kg/day.


Patients with a homozygous c.454+3A>G variant in the TRAPPC4 gene may present with early-onset seizures, microcephaly, sensory neural hearing loss, visual problems and spastic quadriparesis.[2],[3] Increased serum CK levels, indicating muscle involvement in an Indian family with the c.454+3A>G variant and two Indian families with a novel missense variant NM_0161146.6:C191T>C p. (Leu64Pro) in TRAPPC4 have recently been reported, while elevated CK has been reported in other trappopathies.[5],[6] However, our patient had normal serum CK and lactate levels without any muscle involvement. Some patients exhibit frequent infections, which can lead to death in the first decade, at a mean age of 8.8 years.[3] In addition to atopic dermatitis, our patient had low levels of IgA, which has not previously been reported as part of the syndrome. Searching for immunodeficiency in these patients exhibiting frequent infections might expand the phenotype.

A variety of seizures, including spasms, occur early in NEDESBA. Epileptiform abnormalities, generalized disorganization and very low voltage background activity are reported.[2],[3] Brain MRI findings show a variable degree of progressive cerebral atrophy with an increased severity in older age.[3] Enlarged subarachnoid spaces, loss of white matter, enlarged ventricles and cerebellar atrophy have also been reported frequently.[2],[3],[5] However, brain involvement with early-onset seizures, and spasticity are the main presenting symptoms of many neurodegenerative disorders in infancy.[7] Early-onset epileptic encephalopathies, lysosomal storage diseases, such as NCL, and mitochondrial encephalopathies present with prominent gray matter involvement, whereas white matter involvement occurs in disorders with demyelination, such as MLD and Krabbe disease. Basal ganglia and cerebellum involvement is present in leuco-axonopathies, like GM1 and GM2 gangliosidosis, mitochondrial encephalopathies, organic acidurias and Lesch Nyhan syndrome.[7] Before proceeding to next-generation sequencing, a thorough metabolic workup in order to exclude neurodegenerative diseases, which may present with a similar phenotype is advisable. This metabolic workup did not detect any abnormalities in our patient.

In the presented patient, spasms and very low voltage activity on EEG early in the course, led to a second MRI showing severe cortical atrophy, indicating the progressive course of the disease. Our patient also developed optic atrophy, which was not present at the first ophthalmological examination. Eye problems occur in most of the TRAPPC4 patients with absence of pursuit and optic atrophy.[2],[3],[5]

Many new and rare developmental disorders have been described as a result of development in next-generation sequencing technology.[8],[9],[10] Whole-exome sequencing and whole-genome sequencing tests provide a diagnostic yield rate of between 25% and 65% and reduce the 'diagnostic odyssey'.[9],[10] Phenotype-guided genetic tests are reported to achieve a diagnostic confirmation of up to 94%.[9] One of the families reported by Van Bergen et al.[2] as having a homozygous c.454+3A>G variant in TRAPPC4 was from Turkey. Currently, patients with a homozygous c. 454 + 3A > G variant of TRAPPC4 have been reported from European, Mediterranean, Middle Eastern and Indian ancestries, not only in relatives but also in unrelated families.[2],[3],[5],[6] Carrier frequency of this neurodevelopmental and neurodegenerative disorder, NEDESBA, has been reported to be relatively high, varying from 2.4-5.4 per 10 000 individuals worldwide, and mostly frequent in Mediterranean and European ancestries.[3] It is likely, given the relatively high carrier frequency, more patients with NEDESBA will be diagnosed. In patients presenting with severe microcephaly, typical dysmorphic facial features, early-onset seizures with very low voltage, abnormal EEG and progressive cortical atrophy, a TRAPPC4-related neurodevelopmental disorder should be considered in the differential diagnosis of neurodegenerative diseases.


ALT: alanine aminotransferase

AST: aspartate transaminase

CK: Creatine kinase

EEG: Electroencephalography

HC: Head circumference

Ig: Immunoglobulins

LEV: Levetiracetam

MLD: metachromatic leucodystrophy

MRI: Magnetic resonance imaging

NCL: neuronal ceroid lipofuchsinosis

NEDESBA: Neurodevelopmental Disorder with Epilepsy, Spasticity and Brain Atrophy

SDs: Standard deviations

TCC: Thin corpus callosum

TRAPP: TRAnsport Protein Particle

TRAPPC4: TRAnsport Protein Particle complex, subunit C4

WES: Whole exome sequencing.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Sacher M, Shahrzad N, Kamel H, Milev MP. TRAPPopathies: An emerging set of disorders linked to variations in the genes encoding transport protein particle (TRAPP)-associated proteins. Traffic 2019;20:5-26.
2Van Bergen NJ, Guo Y, Al-Deri N, Lipatova Z, Stanga D, Zhao S, et al. Deficiencies in vesicular transport mediated by TRAPPC4 are associated with severe syndromic intellectual disability. Brain 2020;143:112-30.
3Ghosh SG, Scala M, Beetz C, Helman G, Stanley V, Yang X, et al. A relatively common homozygous TRAPPC4 splicing variant is associated with an early-infantile neurodegenerative syndrome. Eur J Hum Genet 2021;29:271-9.
4Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A comprehensive online calculator for pediatric endocrinologists: ÇEDD Çözüm/TPEDS metrics. J Clin Res Pediatr Endocrinol 2017;9:182-4.
5Kaur P, Kadavigere R, Girisha KM, Shukla A. Recurrent bi-allelic splicing variant c. 454+3A>G in TRAPPC4 is associated with progressive encephalopathy and muscle involvement. Brain 2020;143:e29.
6Majethia P, Do Rosario MC, Kaur P, Karanvir, Shankar R, Sharma S, et al. Further evidence of muscle involvement in neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy. Ann Hum Genet 2021. doi: 10.1111/ahg. 12452.
7Mastrangelo M. Clinical approach to neurodegenerative disorders in childhood: An updated overview. Acta Neurol Belg 2019;119:511-21.
8Lee HF, Chi CS, Tsai CR. Diagnostic yield and treatment impact of whole-genome sequencing in paediatric neurological disorders. Dev Med Child Neurol 2021;63:934-8.
9Rexach J, Lee H, Martinez-Agosto JA, Németh AH, Fogel BL. Clinical application of next-generation sequencing to the practice of neurology. Lancet Neurol 2019;18:492-503.
10Sun H, Shen XR, Fang ZB, Jiang ZZ, Wei XJ, Wang ZY, et al. Next-generation sequencing technologies and neurogenetic diseases. Life (Basel) 2021;11:361.